← Leaderboards
Wendy L Picking
University Of Missouri-Columbia
$15,895,808
Attributed
$17,626,601
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,222,065 · 13
By mechanism
R01$14,944,852 · 5
UC7$2,595,464 · 1
R21$2,539,117 · 6
R03$142,632 · 1
Top collaborators
- Marcela F Pasetti5 shared
- Deborah M Anderson1 shared
Most similar at University Of Missouri-Columbia
Same institution · by research overlap
- Deborah M Anderson$5,225,128
- Adam T Whaley Connell$146,350
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsInfectionVaccinesType Iii Secretion System PathwayCellsShigellaPathogenAntigensNovel VaccinesImmune ResponseAdjuvantPathogenesisNeedlesPreventCytoplasmMutantVaccinatedLungStructureInvestigationMolecularSurfaceProtective EfficacyBase
Grant awards (38)
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa$772,498
R01 · FY2025 · AI · contact PI
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa$772,498
R01 · FY2024 · AI · contact PI
Targeting T3SA proteins as protective antigens against Yersinia$194,495
R21 · FY2024 · AI · contact PI
An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691)$193,930
R21 · FY2024 · AI · contact PI
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory$2,595,464
UC7 · FY2023 · AI · contact PI
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa$800,748
R01 · FY2023 · AI · contact PI
Targeting T3SA proteins as protective antigens against Yersinia$231,360
R21 · FY2023 · AI · contact PI
An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691)$229,665
R21 · FY2023 · AI · contact PI
Vaccines to counter emerging antibiotic resistance (R01AI138970)$1,258,174
R01 · FY2022 · AI · contact PI
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa$195,625
R21 · FY2022 · AI · contact PI
Vaccines to counter emerging antibiotic resistance$1,121,304
R01 · FY2021 · AI · contact PI
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa$227,250
R21 · FY2021 · AI · contact PI
Vaccines to counter emerging antibiotic resistance$1,121,364
R01 · FY2020 · AI · contact PI
Vaccines to counter emerging antibiotic resistance$1,114,852
R01 · FY2019 · AI · contact PI
Development of a broadly protective subunit vaccine against Pseudomonas aeruginosa$237,875
R21 · FY2019 · AI · contact PI
Development of a next generation vaccine to prevent pertussis$189,375
R21 · FY2019 · AI · contact PI
Vaccines to counter emerging antibiotic resistance$1,398,346
R01 · FY2018 · AI · contact PI
Development of a next generation vaccine to prevent pertussis$227,250
R21 · FY2018 · AI · contact PI
Development of a broadly protective subunit vaccine against Pseudomonas aeruginosa$189,375
R21 · FY2018 · AI · contact PI
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.$375,000
R01 · FY2017 · AI · contact PI
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.$375,000
R01 · FY2016 · AI · contact PI
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.$375,000
R01 · FY2015 · AI · contact PI
Stable needleless vaccine against Shigella spp$187,000
R21 · FY2015 · AI · contact PI
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogens$640,986
R01 · FY2014 · AI
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.$375,000
R01 · FY2014 · AI · contact PI
Stable needleless vaccine against Shigella spp$235,917
R21 · FY2014 · AI · contact PI
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogens$607,356
R01 · FY2013 · AI
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogens$648,884
R01 · FY2012 · AI
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogens$649,142
R01 · FY2011 · AI
Control of Type III secretion in Shigella by lpaD$352,443
R01 · FY2011 · AI · contact PI
A. L. lactis-based vaccine for children with broad spectrum for enteric pathogens$683,858
R01 · FY2010 · AI
Control of Type III secretion in Shigella by lpaD$356,079
R01 · FY2010 · AI · contact PI
Control of Type III secretion in Shigella by lpaD$368,728
R01 · FY2009 · AI · contact PI
Control of Type III secretion in Shigella by lpaD$74,484
R01 · FY2009 · AI · contact PI
Control of Type III secretion in Shigella by lpaD$348,096
R01 · FY2008 · AI · contact PI
IpaD triggers type III secretion in Shigella$70,632
R03 · FY2008 · AI · contact PI
Control of Type III secretion in Shigella by lpaD$355,012
R01 · FY2007 · AI · contact PI
IpaD triggers type III secretion in Shigella$72,000
R03 · FY2007 · AI · contact PI